Drug Profile

Research programme: bradykinin B2 receptor antagonists - Pharvaris

Alternative Names: PHAxxx

Latest Information Update: 06 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pharvaris
Class Skin disorder therapies; Small molecules; Vascular disorder therapies
Mechanism of Action Bradykinin B2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Hereditary angioedema; Unspecified

Most Recent Events

06 Aug 2025 Early research and development is ongoing in the Netherlands (Pharvaris pipeline, August 2025)
06 Aug 2025 Early research in Unspecified in Netherlands (PO) prior to August 2025 (Pharvaris pipeline, August 2025)
28 Feb 2025 No recent reports of development identified for research development in Hereditary-angioedema in Netherlands (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com